U of T spin-off company, Interface Biologics Inc. (IBI), founded by Professor Paul Santerre (Director, IBBME), continues to garner technical and commercial success.

On December 6, IBI announced a $1-million investment by Ontario’s Investment Accelerator Fund – Life Sciences (IAF-LS). The IAF-LS helps accelerate the growth of life sciences companies that have the potential to be global leaders in their field and provide sustainable economic benefits to the province.

IBI’s unique materials, such as its Endexo Technology, improve the safety and effectiveness of blood contacting medical devices without changing the mechanical or functional properties – and with minimal manufacturing changes. This announcement also coincides with the company’s 10th anniversary.

In July, IBI announced that the largest provider of dialysis products, Fresenius Medical Care, would apply the company’s Endexo Technology to dialysis circuits for treating end-stage renal disease. And in October, Navilyst Medical launched BioFlo, a peripherally inserted central catheter (PICC) that will use Endexo in five clinical centres in Canada.

As part of the IAF-LS funding, IBI will explore the use of its technology platforms in ophthalmology applications.

“We are very pleased that IAF-LS has made this strategic investment in Interface Biologics, providing  financial support to further the commercialization of its innovative technologies,” said Professor Santerre. “This announcement is another example of IBBME’s success in transferring innovative biomaterials and biomedical technology to the healthcare market.”